Secreted heat shock protein-90 (Hsp90) in wound healing and cancer

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 3, 2012, Pages 730-741

  Li, Wei ^a   Sahu, Divya ^a   Tsen, Fred ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Secreted Hsp90; Wound healing

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BECAPLERMIN; EXTRACELLULAR HEAT SHOCK PROTEIN 90; EXTRACELLULAR HEAT SHOCK PROTEIN 90 ALPHA; GELATINASE A; GELDANAMYCIN; GROWTH FACTOR; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; INTEGRIN; INTRACELLULAR HEAT SHOCK PROTEIN 90; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA3; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INVASION; CELL DEATH; CELL MIGRATION; CELL MOTILITY; EXOSOME; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE BINDING; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY; TUMOR CELL; TUMOR GROWTH; WOUND; WOUND CLOSURE; WOUND HEALING;

AMINO ACID SEQUENCE; ANIMALS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; SIGNAL TRANSDUCTION; WOUND HEALING;

MUS;

EID: 84857038878     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.09.009     Document Type: Review

References (91)

1. Martin P. Wound healing - aiming for perfect skin regeneration. Science 1997, 276:75-81.
2. Singer A.J., Clark R.A. Cutaneous wound healing. N. Engl. J. Med. 1999, 341:738-746.
3. Werner S., Grose R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 2003, 83:835-870.
4. Grose R., Werner S. Wound-healing studies in transgenic and knockout mice. Mol. Biotechnol. 2004, 28:147-166.
5. LeGrand E.K. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing. Am. J. Surg. 1998, 176:48S-54S.
6. Steed D.L. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic ulcer study group. J. Vasc. Surg. 1995, 21:71-78. (discussion 79-81).
7. Wieman T.J., Smiell J.M., Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998, 21:822-827.
8. Nagai M.K., Embil J.M. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert. Opin. Biol. Ther. 2002, 2:211-218.
9. Mandracchia V.J., Sanders S.M., Frerichs J.A. The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers. A retrospective analysis. Clin. Podiatr. Med. Surg. 2001, 18:189-209. (viii).
10. Li W., Li Y., Guan S., Fan J., Cheng C.F., Bright A.M., Chinn C., Chen M., Woodley D.T. Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. EMBO J. 2007, 26:1221-1233.
11. Cheng C.F., Fan J., Fedesco M., Guan S., Li Y., Bandyopadhyay B., Bright A.M., Yerushalmi D., Liang M., Chen M., Han Y.P., Woodley D.T., Li W. Transforming growth factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich environment during wound healing. Mol. Cell. Biol. 2008, 28:3344-3358.
12. C.F. Cheng, D. Sahu, F. Tsen, Z. Zhao, J. Fan, X. Wang, R. Kim, Y. Kuang, M. Chen, D.T. Woodley, W. Li, A fragment of secreted Hsp90alpha carries unique properties to accelerate acute and chronic wound healing. J. Clin. Invest. 121 (2011). November.
13. Csermely P., Schnaider T., Soti C., Prohaszka Z., Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 1998, 79:129-168.
14. Cheng C.F., Fan J., Zhao Z., Woodley D.T., Li W. Secreted heat shock protein-90alpha: a more effective and safer target for anti-cancer drugs?. Curr. Signal Trans. Ther. 2010, 5:121-127.
15. Tsutsumi S., Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci. 2007, 98:1536-1539.
16. Liao D.F., Jin Z.G., Baas A.S., Daum G., Gygi S.P., Aebersold R., Berk B.C. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J. Biol. Chem. 2000, 275:189-196.
17. Kuroita T., Tachibana H., Ohashi H., Shirahata S., Murakami H. Growth stimulating activity of heat shock protein 90 alpha to lymphoid cell lines in serum-free medium. Cytotechnology 1992, 8:109-117.
18. Schmitt E., Gehrmann M., Brunet M., Multhoff G., Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leukoc. Biol. 2007, 81:15-27.
19. Basu S., Srivastava P.K. Heat shock proteins: the fountainhead of innate and adaptive immune responses. Cell Stress Chaperones 2000, 5:443-451.
20. Binder R.J., Vatner R., Srivastava P. The heat-shock protein receptors: some answers and more questions. Tissue Antigens 2004, 64:442-451.
21. Gopal U., Bohonowych J.E., Lema-Tome C., Liu A., Garrett-Mayer E., Wang B., Isaacs J.S. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS One 2011, 6:e17649.
22. Gasc J.M., Renoir J.M., Radanyi C., Joab I., Tuohimaa P., Baulieu E.E. Progesterone receptor in the chick oviduct: an immunohistochemical study with antibodies to distinct receptor components. J. Cell Biol. 1984, 99:1193-1201.
23. Welch W.J., Feramisco J.R. Purification of the major mammalian heat shock proteins. J. Biol. Chem. 1982, 257:14949-14959.
24. Catelli M.G., Joab I., Renoir J.M., Mester J., Binart N., Radanyi C., Buchou T., Zoorob R., Baulieu E.E. 402 immunological studies of chick oviduct progesterone receptor. J. Steroid Biochem. 1983, 19:134.
25. Lai B.T., Chin N.W., Stanek A.E., Keh W., Lanks K.W. Quantitation and intracellular localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies. Mol. Cell. Biol. 1984, 4:2802-2810.
26. Ferrarini M., Heltai S., Zocchi M.R., Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int. J. Cancer 1992, 51:613-619.
27. Jameel A., Skilton R.A., Campbell T.A., Chander S.K., Coombes R.C., Luqmani Y.A. Clinical and biological significance of HSP89 alpha in human breast cancer. Int. J. Cancer 1992, 50:409-415.
28. Ghaemmaghami S., Huh W.K., Bower K., Howson R.W., Belle A., Dephoure N., O'Shea E.K., Weissman J.S. Global analysis of protein expression in yeast. Nature 2003, 425:737-741.
29. Pick E., Kluger Y., Giltnane J.M., Moeder C., Camp R.L., Rimm D.L., Kluger H.M. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 2007, 67:2932-2937.
30. Wang X., Heuvelman D.M., Carroll J.A., Dufield D.R., Masferrer J.L. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells. Cancer Invest. 2010, 28:635-641.
31. Kubota H., Yamamoto S., Itoh E., Abe Y., Nakamura A., Izumi Y., Okada H., Iida M., Nanjo H., Itoh H., Yamamoto Y. Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinoma. Cell Stress Chaperones 2010, 15:1003-1011.
32. D. Sahu, Z. Zhao, F. Tsen, C-F Cheng, P. Ryan, J. Fan, J. Dai, A. Eginli, S. Shams, M. Chen, P. Conti, D. T. Woodley, W. Li, Identification of a novel tumor epitope in secreted Hsp90α for HIF-1α-overexpressing breast cancer. Mol. Biol. Cell (in press).
33. Multhoff G., Hightower L.E. Cell surface expression of heat shock proteins and the immune response. Cell Stress Chaperones 1996, 1:167-176.
34. Hightower L.E., Guidon P.T. Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. J. Cell. Physiol. 1989, 138:257-266.
35. Clayton A., Turkes A., Navabi H., Mason M.D., Tabi Z. Induction of heat shock proteins in B-cell exosomes. J. Cell Sci. 2005, 118:3631-3638.
36. Yu X., Harris S.L., Levine A.J. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006, 66:4795-4801.
37. Tsutsumi S., Mollapour M., Graf C., Lee C.T., Scroggins B.T., Xu W., Haslerova L., Hessling M., Konstantinova A.A., Trepel J.B., Panaretou B., Buchner J., Mayer M.P., Prodromou C., Neckers L. Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nat. Struct. Mol. Biol. 2009, 16:1141-1147.
38. Wang X., Song X., Zhuo W., Fu Y., Shi H., Liang Y., Tong M., Chang G., Luo Y. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:21288-21293.
39. Woodley D.T., Fan J., Cheng C.F., Li Y., Chen M., Bu G., Li W. Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90alpha autocrine signaling to promote keratinocyte migration. J. Cell Sci. 2009, 122:1495-1498.
40. Simon M.C., Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat. Rev. Mol. Cell Biol. 2008, 9:285-296.
41. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 2007, 12:853-859.
42. Eustace B.K., Sakurai T., Stewart J.K., Yimlamai D., Unger C., Zehetmeier C., Lain B., Torella C., Henning S.W., Beste G., Scroggins B.T., Neckers L., Ilag L.L., Jay D.G. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol. 2004, 6:507-514.
43. Suzuki S., Kulkarni A.B. Extracellular heat shock protein HSP90beta secreted by MG63 osteosarcoma cells inhibits activation of latent TGF-beta1. Biochem. Biophys. Res. Commun. 2010, 398:525-5331.
44. Chen J.S., Hsu Y.M., Chen C.C., Chen L.L., Lee C.C., Huang T.S. Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression. J. Biol. Chem. 2010, 285:25458-25466.
45. Tsutsumi S., Scroggins B., Koga F., Lee M.J., Trepel J., Felts S., Carreras C., Neckers L. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2008, 27:2478-2487.
46. Denzer K., Kleijmeer M.J., Heijnen H.F., Stoorvogel W., Geuze H.J. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J. Cell Sci. 2000, 113(Pt 19):3365-3374.
47. Thery C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2:569-579.
48. Lancaster G.I., Febbraio M.A. Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J. Biol. Chem. 2005, 280:23349-23355.
49. Savina A., Furlan M., Vidal M., Colombo M.I. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J. Biol. Chem. 2003, 278:20083-20090.
50. Mignot G., Roux S., Thery C., Segura E., Zitvogel L. Prospects for exosomes in immunotherapy of cancer. J. Cell. Mol. Med. 2006, 10:376-388.
51. Hegmans J.P., Bard M.P., Hemmes A., Luider T.M., Kleijmeer M.J., Prins J.B., Zitvogel L., Burgers S.A., Hoogsteden H.C., Lambrecht B.N. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am. J. Pathol. 2004, 164:1807-1815.
52. Young J.C., Moarefi I., Hartl F.U. Hsp90: a specialized but essential protein-folding tool. J. Cell Biol. 2001, 154:267-273.
53. Song X., Wang X., Zhuo W., Shi H., Feng D., Sun Y., Liang Y., Fu Y., Zhou D., Luo Y. The regulatory mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2 processing and tumor angiogenesis. J. Biol. Chem. 2010, 285:40039-40049.
54. Stellas D., El Hamidieh A., Patsavoudi E. Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol. 2010, 11:51.
55. Sidera K., Samiotaki M., Yfanti E., Panayotou G., Patsavoudi E. Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J. Biol. Chem. 2004, 279:45379-45388.
56. Sidera K., Gaitanou M., Stellas D., Matsas R., Patsavoudi E. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J. Biol. Chem. 2008, 283:2031-2041.
57. McCready J., Sims J.D., Chan D., Jay D.G. Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer 2010, 10:294-299.
58. Chung S.W., Lee J.H., Choi K.H., Park Y.C., Eo S.K., Rhim B.Y., Kim K. Extracellular heat shock protein 90 induces interleukin-8 in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2009, 378:444-449.
59. Herz J., Strickland D.K. LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 2001, 108:779-784.
60. Strickland D.K., Ashcom J.D., Williams S., Burgess W.H., Migliorini M., Argraves W.S. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J. Biol. Chem. 1990, 265:17401-17404.
61. Kristensen T., Moestrup S.K., Gliemann J., Bendtsen L., Sand O., Sottrup-Jensen L. Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor. FEBS Lett. 1990, 276:151-155.
62. Van Leuven F., Stas L., Raymakers L., Overbergh L., De Strooper B., Hilliker C., Lorent K., Fias E., Umans L., Torrekens S., et al. Molecular cloning and sequencing of the murine alpha-2-macroglobulin receptor cDNA. Biochim. Biophys. Acta 1993, 1173:71-74.
63. Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313.
64. Ogden C.A., deCathelineau A., Hoffmann P.R., Bratton D., Ghebrehiwet B., Fadok V.A., Henson P.M. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J. Exp. Med. 2001, 194:781-795.
65. Vandivier R.W., Ogden C.A., Fadok V.A., Hoffmann P.R., Brown K.K., Botto M., Walport M.J., Fisher J.H., Henson P.M., Greene K.E. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J. Immunol. 2002, 169:3978-3986.
66. Habich C., Baumgart K., Kolb H., Burkart V. The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins. J. Immunol. 2002, 168:569-576.
67. Lillis A.P., Van Duyn L.B., Murphy-Ullrich J.E., Strickland D.K. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 2008, 88:887-918.
68. Lillis A.P., Mikhailenko I., Strickland D.K. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J. Thromb. Haemost. 2005, 3:1884-1893.
69. Bandyopadhyay B., Fan J., Guan S., Li Y., Chen M., Woodley D.T., Li W. A "traffic control" role for TGFbeta3: orchestrating dermal and epidermal cell motility during wound healing. J. Cell Biol. 2006, 172:1093-1105.
70. Bachman K.E., Park B.H. Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Curr. Opin. Oncol. 2005, 17:49-54.
71. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
72. Papadopoulos N., Nicolaides N.C., Liu B., Parsons R., Lengauer C., Palombo F., D'Arrigo A., Markowitz S., Willson J.K., Kinzler K.W., et al. Mutations of GTBP in genetically unstable cells. Science 1995, 268:1915-1917.
73. Chen T., Triplett J., Dehner B., Hurst B., Colligan B., Pemberton J., Graff J.R., Carter J.H. Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res. 2001, 61:4679-4682.
74. Pinto M., Oliveira C., Cirnes L., Carlos Machado J., Ramires M., Nogueira A., Carneiro F., Seruca R. Promoter methylation of TGFbeta receptor I and mutation of TGFbeta receptor II are frequent events in MSI sporadic gastric carcinomas. J. Pathol. 2003, 200:32-38.
75. Hahm K.B., Im Y.H., Lee C., Parks W.T., Bang Y.J., Green J.E., Kim S.J. Loss of TGF-beta signaling contributes to autoimmune pancreatitis. J. Clin. Invest. 2000, 105:1057-1065.
76. Howe J.R., Roth S., Ringold J.C., Summers R.W., Jarvinen H.J., Sistonen P., Tomlinson I.P., Houlston R.S., Bevan S., Mitros F.A., Stone E.M., Aaltonen L.A. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998, 280:1086-1088.
77. O'Toole E.A., Marinkovich M.P., Peavey C.L., Amieva M.R., Furthmayr H., Mustoe T.A., Woodley D.T. Hypoxia increases human keratinocyte motility on connective tissue. J. Clin. Invest. 1997, 100:2881-2891.
78. Li Y., Fan J., Chen M., Li W., Woodley D.T. Transforming growth factor-alpha: a major human serum factor that promotes human keratinocyte migration. J. Invest. Dermatol. 2006, 126:2096-2105.
79. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
80. Catrina S.B., Okamoto K., Pereira T., Brismar K., Poellinger L. Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes 2004, 53:3226-3232.
81. Botusan I.R., Sunkari V.G., Savu O., Catrina A.I., Grunler J., Lindberg S., Pereira T., Yla-Herttuala S., Poellinger L., Brismar K., Catrina S.B. Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19426-19431.
82. Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313.
83. Dales J.P., Garcia S., Meunier-Carpentier S., Andrac-Meyer L., Haddad O., Lavaut M.N., Allasia C., Bonnier P., Charpin C. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int. J. Cancer 2005, 116:734-739.
84. Lundgren K., Holm C., Landberg G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cell. Mol. Life Sci. 2007, 64:3233-3247.
85. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
86. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., Neckers L.M. Inhibition of heat shock protein HSP90-pp 60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8324-8328.
87. Neckers L., Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin. Emerg. Drugs 2002, 7:277-288.
88. Solit D.B., Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov. Today 2008, 13:38-43.
89. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10:537-549.
90. Louvion J.F., Warth R., Picard D. Two eukaryote-specific regions of Hsp82 are dispensable for its viability and signal transduction functions in yeast. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13937-13942.
91. Dvorack H.F. Tumors: wounds that do not heal. N. Engl. J. Med. 1986, 315:1650-1659.